Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 21,412 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase II Clear all

Conditions: Ependymoma, Anaplastic Ependymoma
Interventions: Carboplatin, Bevacizumab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Blood Loss, Surgical, Prostate Cancer, Surgery
Interventions: Hemospan (MP4OX), Ringer's lactate; Drug
Lead sponsor: Sangart; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Postoperative Hemorrhage
Interventions: Fibrocaps (fibrin sealant), Gelfoam; Device
Lead sponsor: Mallinckrodt; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
Interventions: Not listed
Lead sponsor: Miltenyi Biomedicine GmbH; Industry
Eligibility: 1 Year to 66 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Recurrent/Refractory Glioblastoma
Interventions: crenolanib; Drug
Lead sponsor: Arog Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions: ispinesib, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Bladder Cancer, High Grade, Non Muscle Invasive
Interventions: oncolytic adenovirus expressing GMCSF; Biological
Lead sponsor: CG Oncology, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Levocarnitine, Adefovir dipivoxil, Saquinavir, Lamivudine, Stavudine, Zidovudine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 16 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • San Francisco, California + 9 more

Conditions: Lymphoma
Interventions: biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis; Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 16 Years and older
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2011
U.S. locations: 191
States / cities: Anchorage, Alaska • Berkeley, California • Burlingame, California + 127 more

Conditions: Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma
Interventions: Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Placebo Administration, Sargramostim; Drug · Other · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 12
States / cities: Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 8 more

Conditions: HER2/Neu+ Uterine Serous Carcinoma
Interventions: Afatinib; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 3
States / cities: Tucson, Arizona • New Haven, Connecticut • Boston, Massachusetts

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Liver, Metastatic Malignant Neoplasm in the Lung, Metastatic Malignant Solid Neoplasm
Interventions: Hafnium Oxide-containing Nanoparticles NBTXR3, Radiation Therapy; Other · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: PH-797804, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 22
States / cities: Mobile, Alabama • Glendale, Arizona • San Diego, California + 17 more

Conditions: PTSD
Interventions: TNX-102 SL, Placebo; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 23
States / cities: Tuscaloosa, Alabama • Phoenix, Arizona • Imperial, California + 20 more

Conditions: B-cell Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia
Interventions: Blinatumomab; Drug
Lead sponsor: Michael Burke; Other
Eligibility: Up to 25 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Graft Versus Host Disease, Lymphoma
Interventions: carmustine, melphalan, etoposide, cytarabine, tacrolimus, methotrexate, sargramostim, transplant; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: Up to 59 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 48
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more

Conditions: Leukemia
Interventions: GM-K562 cell vaccine, Interferon alfa, Sargramostim; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
Interventions: Ivonescimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Mesothelioma
Interventions: Nintedanib, Pemetrexed, Cisplatin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 545 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 7 more

Conditions: Liver Cancer, Metastatic Cancer
Interventions: Radiofrequency Ablation; Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Liver Cancers
Interventions: Atezolizumab, Bevacizumab 15 mg/kg, Tiragolumab, Tocilizumab, TPST-1120, Tobemstomig 2100 mg, Bevacizumab 10 mg/kg, Tobemstomig 600 mg, Tobemstomig 1200 mg, ADG126, IO-108 1800 mg, NKT2152, IO-108 1200 mg; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 518 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 16
States / cities: Costa Mesa, California • Duarte, California • Orange, California + 11 more

Conditions: Parkinson Disease, Parkinson Disease Dementia
Interventions: Tributyrin, Placebo; Drug
Lead sponsor: Prabesh Kanel; Other
Eligibility: 45 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Liver Cancer
Interventions: Proton Beam Irradiation; Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 4
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania • Houston, Texas

Conditions: Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: MMSE, QOL via FACT-Br, MRI, Post-operative SRS; Behavioral · Procedure · Radiation
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Carboplatin and Bevacizumab for Recurrent Ependymoma

Safety Study of Hemospan® in Prostatectomy Patients

U.S. Study of Fibrocaps in Surgical Hemostasis

PRAISE-IR Versus CIBMTR Controls

Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination

Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions

Blinatumomab Bridging Therapy for BALL

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)

Nintedanib (BIBF 1120) in Mesothelioma

Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma

Stereotactic Radiosurgery After Surgery in Treating Patients With Brain Metastases